Benitec Biopharma INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. reported beneficial ownership of 10.6% of Benitec Biopharma Inc.'s common stock, including shares from warrants.
NASDAQ
Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Benitec Biopharma Inc. common stock.
NASDAQ
RA Capital Management and its affiliates have disclosed a 5.5% beneficial ownership stake in Benitec Biopharma Inc., holding 1,850,000 shares of common stock.
NASDAQ
Franklin Resources, Inc. and its affiliates updated their beneficial ownership in Benitec Biopharma Inc. to 14.9% of common stock.
NASDAQ
Janus Henderson Group plc and its affiliate have reported a significant beneficial ownership stake of 11.3% in Benitec Biopharma Inc. common stock.
NASDAQ
Janus Henderson Group plc and its affiliates have reported an aggregate beneficial ownership of 11.3% in Benitec Biopharma Inc.'s common stock.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has filed an amended Schedule 13G disclosing a 4.39% beneficial ownership stake in Benitec Biopharma Inc. as of March 31, 2025.
NASDAQ
Janus Henderson Group plc and its affiliates have reported an increased beneficial ownership stake of 11.4% in Benitec Biopharma Inc. common stock as of March 31, 2025.
NASDAQ
Franklin Resources, Inc. and its affiliates, including Franklin Advisers, Inc., have disclosed a beneficial ownership of 16.3% in Benitec Biopharma Inc., totaling 4,415,130 shares as of March 31, 2025.
NASDAQ
Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% of Benitec Biopharma Inc.'s common stock as of December 31, 2024.
NASDAQ
HBM Healthcare Investments (Cayman) Ltd. has filed an amended Schedule 13G, reporting a 4.5% passive beneficial ownership stake in Benitec Biopharma Inc. as of December 31, 2024.
NASDAQ
Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported a combined beneficial ownership of 18.1% of Benitec Biopharma Inc.'s common stock, including shares from warrant exercises.